Covid-19 roundup: Junshi, Eli Lilly ready to launch Covid-19 antibody trial; Janet Woodcock steps aside — for now — as FDA drug czar
Junshi Biosciences and their partners at Eli Lilly say they’re on track to launch the first human trial of a new antibody aimed at fighting Covid-19. The Chinese developer noted that researchers have found 2 antibodies in recovering patients that demonstrate an ability to spur the development of neutralizing antibodies in rhesus monkeys, and they’re rushing straight into a human study to put that preclinical work to the test.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.